Dr. Pier Francesco Ferrucci

Specialised Oncologist

Melanoma – Cutaneous tumours – Immunotherapy – Targeted Therapy

“Two aspects make my activity worthy of being lived with the same conviction and enthusiasm as during my years of study, with the addition of greater experience.

First, the strong and deep relationship established with people affected by tumours, who need assistance and support, sometimes more than a cure. Support that I also wanted to provide through a dedicated Charity Foundation that I established 10 years ago.

Secondly the possibility of combining clinical research with basic research in order to make available, without intermediaries, any new treatment that may improve the expectations and quality of life of the people who rely on me"

– Pier Francesco Ferrucci –

IRCCS Istituto Europeo di Oncologia IEO, Milan (since 2013)

– Director of the Melanoma and Cutaneous Tumours Unit, EIO, Milan, Italy.

Clinical and research activity

Dr. Ferrucci carries out clinical and translational research activity focused on melanoma and skin cancers, on Immunotherapy, Targeted therapy and the personalisation of the cure.

Research and university assignments

  • Professor for the “Degree Course in Cardio-circulatory Pathophysiology and Cardio-vascular Perfusion", University of Milan, Italy.
  • Professor for the II level University Master in “Pharmacy and Oncology Medicine” at the University of Milan, Italy.
  • Professor at Educational Masters for IMI (Italian Melanoma Intergroup).
  • Professor at Masterson Immuno-Oncolgy for NIBIT (Italian Network for Bio-Immunotherapy of cancer).
  • Speaker for the Continuing Medical Education Program and Seminars for General Practitioners at the European Institute of Oncology, Italy.
  • Speaker for Advanced Educational European School of Oncology (ESO) international Courses.

Other activities

– Founder and Scientific Director of the “Fondazione Grazia Focacci" Onlus for Oncology research and support for patients and their families.

– Oral presentation and/or Chairman in over 120 national and international meetings.

– Organiser and on the scientific committee of more than 20 international, national or regional meetings.

– Participation as a consultant in the Advisory Boards for Roche, BMS, Novartis, GSK, Amgen, MSD.

– Experience as pricipal investigator in over 50 GCP clinical trials.

– Funding recipient granted by EORTC, NIBIT, MSD, BMS, ROCHE, Novartis, Fondazione Grazia Focacci, 5×1000 and International Consortiums.

Education and Training

Degree in Medicine and Surgery at the University of Pisa, score 110/110.

Certification in Medical Oncology, University of Perugia, 50/50 and honours.

Equivalence in Ematology.

European Certification in Medical Oncology (ESMO), score 56/60.

Registered with the Certified Order of Doctors “Albo dei Medici”

Registration with the Certified Medical Association, Livorno “Albo dei Medici”, n. 2190.

Medical Career

– From 2006 to 2013 Clinical researcher in the Division of Melanoma, within the Department of Surgery at the European Institute of Oncology, (IRCCS) Milan, Italy.

– From 1996 to 2006 Clinical researcher in the Division of Hematology within the Department of Medical Oncology chaired by Prof. A. Goldhirsch at the European Institute of Oncology, (IRCCS) Milan, Italy.

– From 1995 to 1996 Scientist in Molecular Biology in the laboratory of Prof. P.G. Pelicci at the Department of Experimental Oncology of the European Institute of Oncology, (IRCCS) Milan, Italy.

– From 1990 to 1994 Scientist in Molecular Biology at the Prof. P.G. Pelicci Laboratory, Institute of Internal Medicine and Oncological Sciences, University of Perugia, Italy.

– 1990 Clinical practice at the Faculty of Medicine of the Charles University, Hradec Kralovè, Czechoslovakia.

Medical Memberships

Board of NIBIT (Italian Network for Biotherapy of Tumours).

Membership of the Nord-Ovest Oncology Group (GONO).

Membership of the Italian Society of Internal Medicine (1994-2010).

Membership of the Italian Society of Experimental Hematology (SIES).

Membership of the American Association for Cancer Research (AACR).

Membership of the European Society of Medical Oncology (ESMO).

Membership IMI (Italian Melanoma Intergroup).

Member Editorial board Journal “Clinical Medicine Reviews: Oncology” (CMO)

Member EORTC Melanoma Group.

Member AIOM (Associazione Italiana Oncologia Medica).

Member Editorial board of"The Open Biomarkers Journal"


Italian – English

Treated cancer diseases

Cutaneous tumors
Targeted Therapy

Istituto Europeo di Oncologia IEO
Via Ripamonti 435
20141 Milan, Italy


Per prenotare una visita ambulatoriale in libera professione:

Per prenotare una visita ambulatoriale tramite SSN: +39 02 57489001 (CUP)

Online Medical Consultation with Dr. Pier Francesco Ferrucci

Author and co-author of more than 90 scientific medical publications and books. He plays an active role in the promotion of medical knowledge through the publication of articles in important international scientific journals.


Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD.
N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836.

Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.
Martin-Algarra S, Hinshelwood R, Mesnage S, Cebon J, Ferrucci PF, Aglietta M, Neyns B, Chiarion-Sileni V, Lindsay CR, Del Vecchio M, Linardou H, Merelli B, Tonini G, Atkinson V, Freivogel K, Stein D, Dalland L, Lau M, Legenne P, Queirolo P, Millward M.
Melanoma Res. 2019 Oct;29(5):527-532. doi: 10.1097/CMR.0000000000000608.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A.
Nat Med. 2019 Jun;25(6):941-946. doi: 10.1038/s41591-019-0448-9.

Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis.
Conforti F, Pala L, Bagnardi V, Viale G, De Pas T, Pagan E, Pennacchioli E, Cocorocchio E, Ferrucci PF, De Marinis F, Gelber RD, Goldhirsch A.
J Natl Cancer Inst. 2019 May 20. pii: djz094. doi: 10.1093/jnci/djz094.

Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
Marquardt S, Kirstein MM, Brüning R, Zeile M, Ferrucci PF, Prevoo W, Radeleff B, Trillaud H, Tselikas L, Vicente E, Wiggermann P, Manns MP, Vogel A, Wacker FK.
Eur Radiol. 2019 Apr;29(4):1882-1892. doi: 10.1007/s00330-018-5729-z.

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, Banelli B, Ferrero F, Spano L, Tanda E, Ferrucci PF, Martinoli C, Cocorocchio E, Guida M, Tommasi S, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Quaglino P, Fava P, Osella-Abate S, Ascierto PA, Capone M, Simeone E, Romani M, Spagnolo F, Queirolo P; Italian Melanoma Intergroup (IMI).
Cancer Immunol Immunother. 2019 Jan;68(1):97-107. doi: 10.1007/s00262-018-2258-1.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD.
Lancet Oncol. 2018 Nov;19(11):1480-1492. doi: 10.1016/S1470-2045(18)30700-9. Epub 2018 Oct 22. Erratum in: Lancet Oncol. 2018 Dec;19(12):e668. Lancet Oncol. 2018 Nov;19(11):e581.

A meta-analysis of melanoma risk in industrial workers.
Vujic I, Gandini S, Stanganelli I, Fierro MT, Rappersberger K, Sibilia M, Tosti G, Ferrucci PF, Caini S, De Felici MB, Pagliarello C, Quaglino P, Sanlorenzo M; on behalf of IMI, the Italian Melanoma Intergroup.
Melanoma Res. 2018 Oct 26. doi: 10.1097/CMR.0000000000000531.

Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma.
Cocorocchio E, Pala L, Battaglia A, Gandini S, Peccatori FA, Ferrucci PF.
Acta Oncol. 2018 Aug;57(8):1131-1133. doi: 10.1080/0284186X.2018.1449251.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.
Ascierto PA, Bastholt L, Ferrucci PF, Hansson J, Márquez Rodas I, Payne M, Robert C, Thomas L, Utikal JS, Wolter P, Kudlac A, Tuson H, McKendrick J.
Melanoma Res. 2018 Aug;28(4):333-340. doi: 10.1097/CMR.0000000000000455.

CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab.
Queirolo P, Dozin B, Morabito A, Banelli B, Carosio R, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Ascierto PA, Madonna G, Simeone E, De Galitiis F, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Ghilardi L, Merelli B, Fava P, Osella-Abate S, Guidoboni M, Romani M, Ferone D, Spagnolo F, Pistillo MP; Italian Melanoma Intergroup (IMI).
Eur J Cancer. 2018 Jul;97:59-61. doi: 10.1016/j.ejca.2018.04.005.

Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP.
Front Immunol. 2018 Mar 2;9:403. doi: 10.3389/fimmu.2018.00403. eCollection 2018.

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P, Savoia P, Mandalà M, Simeone E, Valpione S, Altomonte M, Spagnolo F, Cocorocchio E, Gandini S, Giannarelli D, Martinoli C.
Ann Oncol. 2018 Feb 1;29(2):524. doi: 10.1093/annonc/mdx059.

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M, Lebbé C, Kirkwood JM, Schachter J, Daniels GA, Hassel J, Cebon J, Gerritsen W, Atkinson V, Thomas L, McCaffrey J, Power D, Walker D, Bhore R, Jiang J, Hodi FS, Wolchok JD.
J Clin Oncol. 2017 Dec 1;35(34):3815-3822. doi: 10.1200/JCO.2016.72.1167.

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J.
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

Signal intensity change on unenhanced T1-weighted images in dentate nucleus and globus pallidus after multiple administrations of gadoxetate disodium: an intraindividual comparative study.
Conte G, Preda L, Cocorocchio E, Raimondi S, Giannitto C, Minotti M, De Piano F, Petralia G, Ferrucci PF, Bellomi M.
Eur Radiol. 2017 Oct;27(10):4372-4378. doi: 10.1007/s00330-017-4810-3.

Health-related quality of life results from the phase III CheckMate 067 study.
Schadendorf D, Larkin J, Wolchok J, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao C, Wagstaff J, Callahan MK, Postow MA, Smylie M, Ferrucci PF, Dummer R, Hill A, Taylor F, Sabater J, Walker D, Kotapati S, Abernethy A, Long GV.
Eur J Cancer. 2017 Sep;82:80-91. doi: 10.1016/j.ejca.2017.05.031.

Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT).
Russo V, Amadori A, Bregni M, Calabrò L, Colombo MP, Di Nicola M, Ferrucci PF, Proietti E, Maio M, Bellone M.
Cytokine Growth Factor Rev. 2017 Aug;36:1-3. doi: 10.1016/j.cytogfr.2017.06.004.

Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma.
Ferrucci PF, Gandini S, Cocorocchio E, Pala L, Baldini F, Mosconi M, Antonini Cappellini GC, Albertazzi E, Martinoli C.
Oncotarget. 2017 Aug 1;8(45):79809-79815. doi: 10.18632/oncotarget.19748. eCollection 2017 Oct 3.

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, Pistillo MP.
Front Immunol. 2017 Apr 12;8:386. doi: 10.3389/fimmu.2017.00386. eCollection 2017. Erratum in: Front Immunol. 2018 Mar 02;9:403.

Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases.
Mandalà M, Galli F, Cattaneo L, Merelli B, Rulli E, Ribero S, Quaglino P, De Giorgi V, Pigozzo J, Sileni VC, Chirco A, Ferrucci PF, Occelli M, Imberti G, Piazzalunga D, Massi D, Tondini C, Queirolo P; Italian Melanoma Intergroup.
J Am Acad Dermatol. 2017 Feb;76(2):264-273.e2. doi: 10.1016/j.jaad.2016.08.066.

Prognostic significance of hematological profiles in melanoma patients.
Gandini S, Ferrucci PF, Botteri E, Tosti G, Barberis M, Pala L, Battaglia A, Clerici A, Spadola G, Cocorocchio E, Martinoli C.
Int J Cancer. 2016 Oct 1;139(7):1618-25. doi: 10.1002/ijc.30215.

Risk of second primary malignancies among 1537 melanoma patients and risk of second primary melanoma among 52 354 cancer patients in Northern Italy.
Caini S, Radice D, Tosti G, Spadola G, Cocorocchio E, Ferrucci PF, Testori A, Pennacchioli E, Fargnoli MC, Palli D, Bazolli B, Botteri E, Gandini S.
J Eur Acad Dermatol Venereol. 2016 Sep;30(9):1491-6. doi: 10.1111/jdv.13645.

Combination of dabrafenib and radiotherapy: could skin toxicity be affected by different irradiation techniques?
Alterio D, Marvaso G, Ferrari A, Alessandro O, Cocorocchio E, Ferrucci PF, Orecchia R, Jereczek-Fossa BA.
BJR Case Rep. 2016 May 8;2(3):20150493. doi: 10.1259/bjrcr.20150493. eCollection 2016.

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.
Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, Guidoboni M, Queirolo P, Savoia P, Mandalà M, Simeone E, Valpione S, Altomonte M, Spagnolo F, Cocorocchio E, Gandini S, Giannarelli D, Martinoli C.
Ann Oncol. 2016 Apr;27(4):732-8. doi: 10.1093/annonc/mdw016. Epub 2016 Jan 22. Erratum in: Ann Oncol. 2018 Feb 1;29(2):524.

Dabrafenib in metastatic melanoma: a monocentric ‘real life’ experience.
Cocorocchio E, Gandini S, Alfieri S, Battaglia A, Pennacchioli E, Tosti G, Spadola G, Barberis M, Leo MD, Riviello C, Pala L, Intelisano A, Martinoli C, Ferrucci PF.
Ecancermedicalscience. 2016 Mar 3;10:624. doi: 10.3332/ecancer.2016.624. eCollection 2016.

Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S, Martinoli C, Fava P, Mocellin S, Campana LG, Quaglino P, Ferrucci PF, Pigozzo J, Astrua C, Testori A, Chiarion-Sileni V.
Eur J Cancer. 2015 Sep;51(14):2086-94. doi: 10.1016/j.ejca.2015.06.130.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD.
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.
Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, Cappellini GC, De Galitiis F, Marchetti P, Amato G, Lazzeri A, Pala L, Cocorocchio E, Martinoli C.
Br J Cancer. 2015 Jun 9;112(12):1904-10. doi: 10.1038/bjc.2015.180.

Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
Ferrucci PF, Minchella I, Mosconi M, Gandini S, Verrecchia F, Cocorocchio E, Passoni C, Pari C, Testori A, Coco P, Munzone E.
Melanoma Res. 2015 Jun;25(3):239-45. doi: 10.1097/CMR.0000000000000146.

Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents.
Tosti G, Cocorocchio E, Pennacchioli E, Ferrucci PF, Testori A, Martinoli C.
Expert Opin Biol Ther. 2014 Jul;14(7):955-67. doi: 10.1517/14712598.2014.902928.

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.
Chiarion-Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabrò L, Marchetti P, De Galitiis F, Testori A, Ferrucci PF, Queirolo P, Spagnolo F, Quaglino P, Carnevale Schianca F, Mandalà M, Di Guardo L, Del Vecchio M.
Br J Cancer. 2014 Apr 2;110(7):1721-6. doi: 10.1038/bjc.2014.126.

Maspin expression and melanoma progression: a matter of sub-cellular localization.
Martinoli C, Gandini S, Luise C, Mazzarol G, Confalonieri S, Giuseppe Pelicci P, Testori A, Ferrucci PF.
Mod Pathol. 2014 Mar;27(3):412-9. doi: 10.1038/modpathol.2013.157.

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.
Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, Ferrucci PF, Marchetti P, De Galitiis F, Queirolo P, Tornari E, Marconcini R, Calabrò L, Maio M.
Eur J Cancer. 2014 Jan;50(1):121-7. doi: 10.1016/j.ejca.2013.09.007.

Sunny holidays before and after melanoma diagnosis are respectively associated with lower Breslow thickness and lower relapse rates in Italy.
Gandini S, De Vries E, Tosti G, Botteri E, Spadola G, Maisonneuve P, Martinoli C, Joosse A, Ferrucci PF, Baldini F, Cocorocchio E, Pennacchioli E, Cataldo F, Bazolli B, Clerici A, Barberis M, Bataille V, Testori A.
PLoS One. 2013 Nov 4;8(11):e78820. doi: 10.1371/journal.pone.0078820. eCollection 2013. Erratum in: PLoS One. 2014;9(7):e101732.

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M.
Lancet Oncol. 2012 Sep;13(9):879-86. doi: 10.1016/S1470-2045(12)70324-8.

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.
Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabrò L, Rossi CD, Giacomo AM, Ferrucci PF, Ridolfi L, Altomonte M, Miracco C, Balestrazzi A, Maio M.
Cancer Immunol Immunother. 2012 Jan;61(1):41-8. doi: 10.1007/s00262-011-1089-0.

Newly identified tumor antigens as promising cancer vaccine targets for malignant melanoma treatment.
Ferrucci PF, Tosti G, di Pietro A, Passoni C, Pari C, Tedeschi I, Cataldo F, Martinoli C, Testori A.
Curr Top Med Chem. 2012;12(1):11-31.

The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease.
di Pietro A, Tosti G, Ferrucci PF, Testori A.
Expert Opin Biol Ther. 2011 Oct;11(10):1395-407. doi: 10.1517/14712598.2011.605353.

Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach.
Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF.
Dermatol Ther. 2010 Nov-Dec;23(6):651-61. doi: 10.1111/j.1529-8019.2010.01370.x.

HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.
Tosti G, di Pietro A, Ferrucci PF, Testori A.
Expert Rev Vaccines. 2009 Nov;8(11):1513-26. doi: 10.1586/erv.09.108.

Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. (IELSG 4). [corrected].
Martinelli G, Gigli F, Calabrese L, Ferrucci PF, Zucca E, Crosta C, Pruneri G, Preda L, Piperno G, Gospodarowicz M, Cavalli F, Moreno Gomez H.
Leuk Lymphoma. 2009 Jun;50(6):925-31. doi: 10.1080/10428190902912478. Erratum in: Leuk Lymphoma. 2009 Nov;50(11):1904. Leuk Lymphoma. 2010 Apr;51(4):733.

Medium adsorbance fraction of reticulocyte and myeloperoxidase index may individuate a patient subset with a low risk of chemotherapy-related neutropenia.
Giordano G, Ferrucci PF, Nicci C, Grafone T, Tambaro R, Papini S, Farina G, Piano S, Zappacosta B, Storti S.
Oncol Rep. 2009 Jan;21(1):193-8.

Oncophage: step to the future for vaccine therapy in melanoma.
di Pietro A, Tosti G, Ferrucci PF, Testori A.
Expert Opin Biol Ther. 2008 Dec;8(12):1973-84. doi: 10.1517/14712590802517970 . Review.

Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.
Lens M, Ferrucci PF, Testori A.
Recent Pat Anticancer Drug Discov. 2008 Jun;3(2):105-13. Review.

Efficacy of 90Y ibritumomab-tiuxetan treatment in a case of resistant gastric MALT non-Hodgkin’s lymphoma.
Ferrucci PF, Vanazzi A, Crosta C, Pruneri G, Grana C, Bartolomei M, Paganelli G, Martinelli G.
Ecancermedicalscience. 2008;2:79. doi: 10.3332/eCMS.2008.79.

High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas.
Ferrucci PF, Vanazzi A, Grana CM, Cremonesi M, Bartolomei M, Chinol M, Ferrari M, Radice D, Papi S, Martinelli G, Paganelli G.
Br J Haematol. 2007 Nov;139(4):590-9.

High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
Cremonesi M, Ferrari M, Grana CM, Vanazzi A, Stabin M, Bartolomei M, Papi S, Prisco G, Ferrucci PF, Martinelli G, Paganelli G.
J Nucl Med. 2007 Nov;48(11):1871-9. Erratum in: J Nucl Med. 2007 Dec;48(12):2027.

A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer.
Ferrucci PF, Rabascio C, Gigli F, Corsini C, Giordano G, Bertolini F, Martinelli G.
Int J Oncol. 2007 Apr;30(4):955-62.

Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?
Ferrucci PF, Zucca E.
Br J Haematol. 2007 Feb;136(4):521-38.

Cerebrospinal fluid diffusion of Zevalin after high-activity treatment and stem cell support in a patient affected by diffuse large B-cell non-Hodgkin’s lymphoma with central nervous system involvement.
Ferrucci PF, Vanazzi A, Tesoriere G, Ferrari M, Bartolomei M, Rocca P, Cremonesi M, Paganelli G, Martinelli G.
Ann Oncol. 2005 Oct;16(10):1710-1.

Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer.
Ferrucci PF, Rabascio C, Mazzetta C, Cocorocchio E, Agazzi A, Vanazzi A, Cinieri S, Peccatori FA, Paolucci M, Bertolini F, Martinelli G.
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6039-46.

ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin’s lymphoma.
Martinelli G, Ferrucci PF, Mingrone W, Cocorocchio E, Conconi A, Peccatori FA, De Luzio K, Santoro P, Mazzetta C, Zucca E, Cavalli F.
Leuk Lymphoma. 2003 May;44(5):801-6. Erratum in: Leuk Lymphoma. 2003 Jul;44(7):1265.

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers.
Bertolini F, Mingrone W, Alietti A, Ferrucci PF, Cocorocchio E, Peccatori F, Cinieri S, Mancuso P, Corsini C, Burlini A, Zucca E, Martinelli G.
Ann Oncol. 2001 Jul;12(7):987-90. Erratum in: Ann Oncol 2001 Sep;12(9):1333. Cineri S [corrected to Cinieri S].

Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma.
Bertolini F, Fusetti L, Mancuso P, Gobbi A, Corsini C, Ferrucci PF, Martinelli G, Pruneri G.
Blood. 2000 Jul 1;96(1):282-7.

Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin.
Corsini C, Ghielmini M, Mancuso P, Tealdo F, Paolucci M, Zucchetti M, Ferrucci PF, Cocorocchio E, Mezzetti M, Mori A, Riggi M, D’Incalci M, Martinelli G.
Br J Cancer. 2000 Feb;82(3):524-8.

Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy.
Ferrucci PF, Martinoni A, Cocorocchio E, Civelli M, Cinieri S, Cardinale D, Peccatori FA, Lamantia G, Agazzi A, Corsini C, Tealdo F, Fiorentini C, Cipolla CM, Martinelli G.
Bone Marrow Transplant. 2000 Jan;25(2):173-7.

Angiogenesis in myelodysplastic syndromes.
Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, Buffa R, Lambertenghi-Deliliers G, Pezzella F.
Br J Cancer. 1999 Dec;81(8):1398-401.

Angiogenic growth factors and endostatin in non-Hodgkin’s lymphoma.
Bertolini F, Paolucci M, Peccatori F, Cinieri S, Agazzi A, Ferrucci PF, Cocorocchio E, Goldhirsch A, Martinelli G.
Br J Haematol. 1999 Aug;106(2):504-9.

Totally implantable central venous access ports for high-dose chemotherapy administration and autologous stem cell transplantation: analysis of overall and septic complications in 68 cases using a single type of device.
Biffi R, Martinelli G, Pozzi S, Cinieri S, Cocorocchio E, Peccatori F, Ferrucci PF, Pistorio R, Andreoni B.
Bone Marrow Transplant. 1999 Jul;24(1):89-93.

Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein.
Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, Pelicci PG, Testi R.
Blood. 1998 Oct 1;92(7):2244-51.

In vitro response to all-trans retinoic acid of acute promyelocytic leukemias with nonreciprocal PML/RARA or RARA/PML fusion genes.
Mozziconacci MJ, Liberatore C, Brunel V, Grignani F, Arnoulet C, Ferrucci PF, Fernandez F, Sainty D, Pelicci PG, Birg F, Lafage-Pochitaloff M.
Genes Chromosomes Cancer. 1998 Jul;22(3):241-50.

Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival.
Fagioli M, Alcalay M, Tomassoni L, Ferrucci PF, Mencarelli A, Riganelli D, Grignani F, Pozzan T, Nicoletti I, Grignani F, Pelicci PG.
Oncogene. 1998 Jun 4;16(22):2905-13.

Cell death induction by the acute promyelocytic leukemia-specific PML/RARalpha fusion protein.
Ferrucci PF, Grignani F, Pearson M, Fagioli M, Nicoletti I, Pelicci PG.
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10901-6.

Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor alpha (RAR alpha) and PLZF-RAR alpha fusion proteins on retinoic acid signalling.
Ruthardt M, Testa U, Nervi C, Ferrucci PF, Grignani F, Puccetti E, Grignani F, Peschle C, Pelicci PG.
Mol Cell Biol. 1997 Aug;17(8):4859-69.

Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.
Grignani F, Testa U, Rogaia D, Ferrucci PF, Samoggia P, Pinto A, Aldinucci D, Gelmetti V, Fagioli M, Alcalay M, Seeler J, Grignani F, Nicoletti I, Peschle C, Pelicci PG.
EMBO J. 1996 Sep 16;15(18):4949-58.

Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia.
Flenghi L, Fagioli M, Tomassoni L, Pileri S, Gambacorta M, Pacini R, Grignani F, Casini T, Ferrucci PF, Martelli MF, et al.
Blood. 1995 Apr 1;85(7):1871-80.

PML/RAR alpha+ U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3.
Testa U, Grignani F, Barberi T, Fagioli M, Masciulli R, Ferrucci PF, Seripa D, Camagna A, Alcalay M, Pelicci PG, et al.
Cancer Res. 1994 Aug 15;54(16):4508-15.

Effect of the acute promyelocytic leukemia PML/RAR alpha protein on differentiation and survival of myeloid precursors.
Fagioli M, Grignani F, Ferrucci PF, Alcalay M, Mencarelli A, Nicoletti I, Grignani F, Pelicci PG.
Leukemia. 1994 Apr;8 Suppl 1:S7-11.

The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells.
Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, et al.
Cell. 1993 Aug 13;74(3):423-31.

The molecular genetics of acute promyelocytic leukemia.
Grignani F, Fagioli M, Ferrucci PF, Alcalay M, Pelicci PG.
Blood Rev. 1993 Jun;7(2):87-93. Review.

La Repubblica, 10 ottobre 2019

Manipolare il sistema immunitario per vincere il cancro

Oggi è possibile manipolare il sistema immunitario per renderlo più forte nel riconoscere e aggredire il tumore. Le cellule T del paziente (linfociti T che agiscono contro la malattia) possono essere prelevate dal sangue periferico o dal tumore, cresciute in grandi quantità in laboratorio e restituite al paziente dopo averle “rinvigorite” (TIL Therapy, Tumor Infiltrating Lymphocyte), o “ingegnerizzate” in modo da riconoscere il bersaglio da eliminare (CAR-T Therapy, Chimeric Antigen Receptor T-cell). Due strategie che rientrano nella terapia cellulare, in particolare nella cosiddetta “immunoterapia adottiva”, la frontiera più avanzata nella lotta contro il cancro, oggi applicata nei tumori del sangue e che, nei prossimi anni, sarà estesa a neoplasie solide come il melanoma, il tumore della mammella, dell’ovaio e il glioblastoma… Continua a leggere su La Repubblica

Corriere della sera, 7 settembre 2019

Io, ragazzo della beffa di Modigliani: non mi pento e sfido il cancro

Trentacinque anni fa, era l’estate del 1984, il suo nome fu per mesi nelle cronache di tutto il mondo per essere stato uno dei protagonisti della «beffa del XX Secolo», tale da far impallidire anche Giovanni Boccaccio. E oggi, quel ragazzo di 20 anni che con due amici, Pietro Luridiana e Michele Ghelarducci, scolpì una pietra col trapano, la gettò nei canali di Livorno dove erano in corso le ricerche delle leggendarie teste di Amedeo Modigliani, facendo credere a eminenti storici dell’arte fosse originale, è diventato un importantissimo oncologo. Il dottor Pier Francesco Ferrucci è direttore di Oncologia del melanoma al prestigioso Istituto Europeo di Oncologia (Ieo) di Milano, fondato da Umberto Veronesi… Continua a leggere su il Corriere della Sera

How to apply for an online medical consultation

Register your details in the secure area and choose the doctor according to your disease.

Fill in the medical history form and upload your reports and clinical exams.

Enter your billing information and make the payment.

Within 5 working days you will receive the doctor’s online consultation.